Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zofenopril SCHEMBL1357585 | 1.00 | ACE (0.98) | ACEKMT2A | |
| Zofenopril SCHEMBL388350 | 1.00 | ACE (0.98) | ACEKMT2A | |
| Zofenopril SCHEMBL641551 | 0.99 | ACE (0.96) | ACEKMT2A | |
| Zofenopril SCHEMBL6508784 | 0.99 | ACE (1.00) | ACEKMT2A | |
| Zofenopril SCHEMBL635414 | 0.99 | ACE (1.00) | ACEKMT2A | |
| Zofenopril SCHEMBL7325874 | 0.99 | ACE (1.00) | ACEKMT2A | |
| Zofenopril SCHEMBL37298 | 0.99 | ACE (1.00) | ACEKMT2A | |
| Zofenopril SCHEMBL22492299 | 0.99 | ACE (1.00) | ACEKMT2A | |
| Zofenopril SCHEMBL22067789 | 0.99 | ACE (1.00) | ACEKMT2A | |
| Zofenopril SCHEMBL10338727 | 0.99 | ACE (1.00) | ACEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 960 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020167748-A1 | THERAPEUTIC COMBINATIONS | SUPERSALUS, INC. (US) | 2020-08-20 | — | — | WO | claimed |
| EP-2245007-B1 | Process for preparing a crystalline form of zofenopril calcium | GENERICS UK LTD (GB) | 2020-08-19 | — | — | EP | claimed |
| CN-110403934-A | New application of medicine zofenopril calcium | UNIV CHINA MEDICAL | 2019-11-05 | — | — | CN | claimed |
| US-10149909-B2 | Fortifier | TORAY INDUSTRIES, INC. (JP) | 2018-12-11 | — | — | US | claimed |
| US-20170080089-A1 | FORTIFIER | TORAY INDUSTRIES, INC. (JP) | 2017-03-23 | — | — | US | claimed |
| CN-104138359-B | The preparation method of zofenopril calcium tablet | Shanghai Haini Pharm Co., Ltd., Yangzijiang Pharm Group (CN) | 2016-03-02 | — | — | CN | claimed |
| US-9221754-B2 | Crystalline forms of zofenopril calcium | GENERICS [UK] LIMITED (GB) | 2015-12-29 | — | — | US | claimed |
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | CATABASIS PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | claimed |
| EP-1899297-B1 | ZOFENOPRIL CALCIUM IN POLYMORPH FORM C | GENERICS UK LTD (GB) | 2015-12-09 | — | — | EP | claimed |
| EP-2941252-A2 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | Catabasis Pharmaceuticals, Inc. (US) | 2015-11-11 | — | — | EP | claimed |
| WO-1991011999-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | claimed |
| WO-1991012001-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | claimed |
| EP-0419048-A2 | Substituted pyrimidinones as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-03-27 | — | — | EP | claimed |
| EP-0412594-A2 | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-02-13 | — | — | EP | claimed |
| EP-0411766-A1 | Substituted quinazolinones as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-02-06 | — | — | EP | claimed |
| EP-0409332-A2 | Substituted triazoles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-01-23 | — | — | EP | claimed |
| EP-0407102-A1 | Substituted imidazo-fused 5-membered ring heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-01-09 | — | — | EP | claimed |
| EP-0400974-A2 | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | claimed |
| EP-0401030-A2 | Angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | claimed |
| EP-0400835-A1 | Substituted benzimidazoles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10149909-B2 | Fortifier | REN, ACE, AGT | ACE 2/4885KMT2A 3003/4885 |
| US-20170080089-A1 | FORTIFIER | REN, ACE, AGT | ACE 2/4885KMT2A 3003/4885 |
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | NAMPT, NNT, FASN | ACE 1402/4885KMT2A 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.